Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DBV Technologies (DBVT) Receivables (2014 - 2023)

DBV Technologies (DBVT) reported Receivables of $1.4 million for Q4 2023, down 10.04% year-over-year from $1.5 million in Q4 2022, and down 10.04% on a QoQ basis from $1.5 million in Q4 2022.

DBV Technologies (DBVT) has 8 years of Receivables data on file, last reported at $1.4 million in Q4 2023.

  • Quarterly Receivables fell 10.04% year-over-year to $1.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.4 million (down 10.04% YoY) and the FY2023 annual result came in at $1.4 million, down 10.04% from the prior year.
  • Receivables eased to $1.4 million in Q4 2023 per DBVT's latest filing, from $1.5 million in the prior quarter.
  • Across five years, Receivables topped out at $2.8 million in Q4 2020 and bottomed at $1.3 million in Q4 2021.
  • The 4-year median for Receivables is $1.4 million (2022), against an average of $1.7 million.
  • The widest annual swing landed in 2021, when Receivables sank 54.39%; it then grew 17.32% in 2022.
  • Tracing DBVT's Receivables over 4 years: stood at $2.8 million in 2020, then slumped by 54.39% to $1.3 million in 2021, then grew by 17.32% to $1.5 million in 2022, then retreated by 10.04% to $1.4 million in 2023.
  • Per Business Quant, the three latest DBVT Receivables figures stand at $1.4 million (Q4 2023), $1.5 million (Q4 2022), and $1.3 million (Q4 2021).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 13.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 4.15 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 2.00 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 5.73 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 883.96 Mn
10 DBV Technologies 8.00 Bn 7.77 Bn -3.90 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2023 1.35 Mn
Dec 31, 2022 1.50 Mn
Dec 31, 2021 1.28 Mn
Dec 31, 2020 2.81 Mn
Dec 31, 2017 2.89 Mn
Dec 31, 2016 3.38 Mn
Jun 30, 2016 11.32 Mn
Dec 31, 2015 1.56 Mn
Dec 31, 2014 170,117.34